Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.54 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945301 | 0.91 | TRPV1 (0.78) | TRPV1LMNAMAPTHTTMEN1 | |
| SCHEMBL10307939 | 0.88 | TRPV1 (0.85) | TRPV1LIMK1LIMK2 | |
| SCHEMBL12073239 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL12074329 | 0.85 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL16248098 | 0.83 | TRPV1 (0.75) | TRPV1 | |
| SCHEMBL10308203 | 0.83 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL16220462 | 0.83 | TRPV1 (0.69) | TRPV1LMNAMAPTHTTMEN1 | |
| SCHEMBL14021827 | 0.83 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL12971681 | 0.82 | TRPV1 (0.62) | TRPV1MAPTALDH1A1LIMK1LIMK2 | |
| SCHEMBL14945287 | 0.82 | TRPV1 (0.76) | TRPV1LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921373-B2 | Compounds having TRPV1 antagonistic activity and uses thereof | SHIONOGI & CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | PURDUE PHARMA L.P. | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123239-A1 | COMPOUNDS HAVING TRPV1 ANTAGONISTIC ACTIVITY AND USES THEREOF | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885LMNA 4369/4885MAPT 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.